The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
Open accessAbstract
Cefiderocol, formerly S-649266, is a first in its class, an injectable siderophore cephalosporin that combines a catechol-type siderophore and cephalosporin core with side chains similar to cefepime and ceftazidime. This structure and its unique mechanism of action confer enhanced stability against hydrolysis by many β-lactamases, including extended spectrum β-lactamases such as CTX-M, and carbapenemases such as KPC, NDM, VIM, IMP, OXA-23, OXA-48-like, OXA-51-like and OXA-58. Cefiderocol's spectrum of activity encompasses both lactose-fermenting and non-fermenting Gram-negative pathogens, including carbapenem-resistant Enterobacterales. Cefiderocol recently received US Food and Drug Administration approval for the treatment of complicated urinary tract infections, including pyelonephritis, and is currently being evaluated in phase III trials for nosocomial pneumonia and infections caused by carbapenem-resistant Gram-negative pathogens. The purpose of this article is to review existing data on the mechanism of action, microbiology, pharmacokinetics, pharmacodynamics, efficacy, and safety of cefiderocol to assist clinicians in determining its place in therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Apart from binding their primary ligand, FeEnt, with high affinity, and its aposiderophore Ent with 100-200-fold lower affinity (38), KpnFepA_1658, KpnIroN, and KpnFepA_4984 showed different preferences for ferric catecholate complexes and siderophore antibiotics cefiderocol [FeFDC (40,41)] and FeMB-1 (42,43):”
From Siderophore-mediated iron acquisition by Klebsiella pneumoniae (2024) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iron in infection and immunity
Cassat, J. E., & Skaar, E. P. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.04.010 · Cited by 1,214
Rodríguez‐Baño, J., Gutiérrez‐Gutiérrez, B., Machuca, I., & Pascual, Á. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 718
Turton, J. F., Woodford, N., Glover, J., Yarde, S., Kaufmann, M. E., & Pitt, T. L. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.01021-06 · Cited by 658
van Duin, D., Lok, J. J., Earley, M. J., Cober, E., Richter, S. S., Pérez, F., Salata, R. A., Kalayjian, R. C., Watkins, R., Doi, Y., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix783 · Cited by 657
Mechanisms of antimicrobial resistance in Gram-negative bacilli
Ruppé, É., Woerther, P., & Barbier, F. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0061-0 · Cited by 523
Shields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Potoski, B. A., Marini, R. V., Doi, Y., Kreiswirth, B. N., & Clancy, C. J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00883-17 · Cited by 496
Wunderink, R. G., Giamarellos‐Bourboulis, E. J., Rahav, G., Mathers, A. J., Bassetti, M., Vázquez, J. A., Cornely, O. A., Solomkin, J. S., Bhowmick, T., Bishara, J., et al. (2018) · Infectious Diseases and Therapy · doi:10.1007/s40121-018-0214-1 · Cited by 464
Zhanel, G. G., Golden, A. R., Zelenitsky, S., Wiebe, K., Lawrence, C. K., Adam, H. J., Idowu, T., Domalaon, R., Schweizer, F., Zhanel, M. A., et al. (2019) · Drugs · doi:10.1007/s40265-019-1055-2 · Cited by 446
Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
Morrill, H. J., Pogue, J. M., Kaye, K. S., & LaPlante, K. L. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv050 · Cited by 436
Self-citationSynthesis, nature and utility of universal iron chelator – Siderophore: A review
Khan, A., Singh, P., & Srivastava, A. (2017) · Microbiological Research · doi:10.1016/j.micres.2017.10.012 · Cited by 430
Cited by
Sorted by citations
Torres, A., Cillóniz, C., Niederman, M. S., Menéndez, R., Chalmers, J. D., Wunderink, R. G., & van der Poll, T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00259-0 · Cited by 904
Antibiotics and Bacterial Resistance—A Short Story of an Endless Arms Race
Baran, A., Kwiatkowska, A., & Potocki, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065777 · Cited by 354
Update of the treatment of nosocomial pneumonia in the ICU
Zaragoza, R., Vidal, P., Aguilar, G., Borges-Sa, M., Dı́az, E., Ferrer, R., Maseda, E., Nieto, M., Nuvials, X., Ramírez, P., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03091-2 · Cited by 238
Rusu, A., Moga, I., Uncu, L., & Hancu, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112554 · Cited by 230
Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens
Saxena, D., Maitra, R., Bormon, R., Czekanska, M., Meiers, J., Titz, A., Verma, S., & Chopra, S. (2023) · npj Antimicrobials and Resistance · doi:10.1038/s44259-023-00016-1 · Cited by 217
Metadata
- Authors
- Wu, J. Y., Srinivas, P., & Pogue, J. M.
- Affiliations
- Cleveland Clinic (US)
- University of Michigan (US)
- Corresponding author
- Wu, Janet Y.
- Venue
- Infectious Diseases and Therapy
- Published
- 2020-02-18
- Volume
- 9
- Issue
- 1
- Pages
- 17-40
- ISSN
- 2193-6382 (ISSN-L)
- 2193-8229
- PMC
- PMC7054475
- OpenAlex
- W3008901682
- Cited by
- 195
- References
- 45
- Citations by year
- 2026: 25 · 2025: 25 · 2024: 25 · 2023: 37 · 2022: 36 · 2021: 28 · 2020: 18
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Infectious Diseases and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Urology › Urinary Tract Infections Management
- Keywords
- cefiderocol, siderophore cephalosporin, multidrug-resistant Gram-negative bacteria, carbapenem resistance, extended-spectrum beta-lactamase, carbapenemase, mechanism of action, pharmacokinetics, pharmacodynamics, complicated urinary tract infection, nosocomial pneumonia, Enterobacterales, drug safety and efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
